Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation and Depletion (2019 - 2024)

Historic Depreciation and Depletion for Allogene Therapeutics (ALLO) over the last 6 years, with Q1 2024 value amounting to $3.6 million.

  • Allogene Therapeutics' Depreciation and Depletion rose 136.87% to $3.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $14.2 million, marking a year-over-year increase of 97.09%. This contributed to the annual value of $14.2 million for FY2023, which is 67.16% down from last year.
  • Per Allogene Therapeutics' latest filing, its Depreciation and Depletion stood at $3.6 million for Q1 2024, which was up 136.87% from $3.5 million recorded in Q4 2023.
  • Allogene Therapeutics' Depreciation and Depletion's 5-year high stood at $4.2 million during Q4 2021, with a 5-year trough of $1.8 million in Q3 2020.
  • Moreover, its 5-year median value for Depreciation and Depletion was $3.5 million (2023), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Depreciation and Depletion surged by 24797.79% in 2020, and later crashed by 2767.56% in 2022.
  • Allogene Therapeutics' Depreciation and Depletion (Quarter) stood at $1.8 million in 2020, then surged by 130.04% to $4.2 million in 2021, then dropped by 27.68% to $3.1 million in 2022, then rose by 13.33% to $3.5 million in 2023, then grew by 2.24% to $3.6 million in 2024.
  • Its last three reported values are $3.6 million in Q1 2024, $3.5 million for Q4 2023, and $3.6 million during Q3 2023.